{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"BrainStorm Announces NurOwn\u00ae Expanded Access Program - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"eLaA8Rkgpr\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/brainstorm-announces-nurown-expanded-access-program\/\">BrainStorm Announces NurOwn\u00ae Expanded Access Program<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/brainstorm-announces-nurown-expanded-access-program\/embed\/#?secret=eLaA8Rkgpr\" width=\"600\" height=\"338\" title=\"&#8220;BrainStorm Announces NurOwn\u00ae Expanded Access Program&#8221; &#8212; Market Newsdesk\" data-secret=\"eLaA8Rkgpr\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"NurOwn\u00ae will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria PR Newswire NEW YORK, Dec. 14, 2020 \/PRNewswire\/ &#8212; BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today the initiation of a NurOwn\u00ae (MSC-NTF cells) \u00a0Expanded Access Program (EAP) for \u00a0patients with amyotrophic lateral sclerosis (ALS) who completed the Company&#8217;s recently concluded pivotal Phase 3 clinical trial and meet specific eligibility requirements. The protocol for the EAP was developed in partnership with the United States Food and Drug Administration (FDA) to provide access to NurOwn for Phase 3 clinical trial participants who meet specific eligibility criteria.\u00a0Initially, patients &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/mma.prnewswire.com\/media\/1166536\/BrainStorm_Logo.jpg"}